Wanhai Institute of Life Sciences

Wanhai Institute of Life Sciences is a Shenzhen-based biotechnology company specializing in regenerative medicine and advanced cellular therapies. The institute focuses on the research, development, and clinical application of mesenchymal stem cells (MSCs) and immune cells, including natural killer (NK) and CAR-T cells. Their primary therapeutic pipeline targets chronic conditions such as knee osteoarthritis, diabetes, and liver cirrhosis, as well as various oncology indications. Wanhai operates a comprehensive ecosystem that includes basic life science research, clinical-grade cell manufacturing, and a large-scale cell bank. The company is positioned as a leader in the Chinese cell therapy sector, bridging the gap between laboratory discovery and clinical health management.